Trip to focus on lupus takes on another purpose
Search results for: Primary care
Exploring the Complement System in Human Disease
Novel disease associations revealed by whole genome screens
Drug Updates: Information on New Approvals and Medication Safety
Information on New Approvals and Medication Safety
Documenting Infusion Time, Start to Finish
Has your practice ever experienced the disappointment of being downcoded because of lack of supporting documentation?
Letters to the Editor: In Memoriam
One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.
Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
A perspective on B cell–targeted therapies in autoimmune disease
Reading Rheum
Handpicked Reviews of Contemporary Literature
I RheumPAC, Do You?
For many years, the ACR board of directors and Government Affairs Committee have done exemplary work in keeping members abreast of legislative regulatory issues that affect all aspects of rheumatology, including patient and physician/healthcare professional issues, education, and research. Through advocacy, the ACR advances rheumatology and fosters excellence in the care of people with, or at risk for, arthritis and rheumatic and musculoskeletal diseases. One might say that advocacy is a cornerstone of this organization.
Practical Medication Management
Take a firm stand in perioperative and pregnant patients with rheumatic disease
Drug Updates
Information on New Approvals and Medication Safety
- « Previous Page
- 1
- …
- 122
- 123
- 124
- 125
- 126
- …
- 129
- Next Page »